Jaundice is the commonest presentation of patients with liver and biliary disease. The cause can be established in most cases by simple non-invasive tests, but many patients will require referral to a specialist for management. Patients with high concentrations of bilirubin (>100 μmol/l) or with evidence of sepsis or cholangitis are at high risk of developing complications and should be referred as an emergency because delays in treatment adversely affect prognosis.
Jaundice, also known as icterus, is a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels.[rx][rx] It is commonly associated with itchiness.[rx] The feces may be pale and the urine dark.[rx] Jaundice in babies occurs in over half in the first week following birth and in most is not a problem.[rx][rx] If bilirubin levels in babies are very high for too long, a type of brain damage, known as kernicterus, may occur.[rx]
Hyperbilirubinaemia is defined as a bilirubin concentration above the normal laboratory upper limit of 19 μmol/l. Jaundice occurs when bilirubin becomes visible within the sclera, skin, and mucous membranes, at a blood concentration of around 40 μmol/l. Jaundice can be categorized as prehepatic, hepatic, or posthepatic, and this provides a useful framework for identifying the underlying cause.
Types of Jaundice
There are three main types of jaundice
- Hepatocellular jaundice – occurs as a result of liver disease or injury.
- Hemolytic jaundice – occurs as a result of hemolysis, or an accelerated breakdown of red blood cells, leading to an increase in the production of bilirubin.
- Obstructive jaundice – occurs as a result of an obstruction in the bile duct. This prevents bilirubin from leaving the liver.
Others
- Physiologic jaundice – Physiologic jaundice occurs as a normal response to the baby’s limited ability to excrete bilirubin in the first days of life.
- Breast milk jaundice – About 2 percent of breastfed babies develop jaundice after the first week. It peaks about two weeks of age and can persist up to three to 12 weeks. Breast milk jaundice is thought to be caused by a substance in the breast milk that increases the reabsorption of bilirubin through the intestinal tract.
- Breastfeeding failure jaundice – It is caused by failure to initiate breastfeeding, resulting in dehydration, decreased urine production and accumulation of bilirubin. Late preterm infants, those who are born between 34 weeks and 36 weeks, are more susceptible to this problem because they do not have the coordination and strength to maintain a successful breastfeeding. However, it is also very common in full-term newborns and usually gets better once breastfeeding is established.
- Jaundice from hemolysis – Jaundice may occur with the breakdown of red blood cells due to hemolytic disease of the newborn (Rh disease), or from having too many red blood cells that break down naturally and release bilirubin.
- Jaundice related to inadequate liver function – Jaundice may be related to inadequate liver function due to infection or other factors.
Causes of Jaundice
Hemolytic
Intrinsic causes of hemolysis
Membrane conditions
- Spherocytosis
- Hereditary elliptocytosis
Enzyme conditions
- Glucose-6-phosphate dehydrogenase deficiency (also called G6PD deficiency)
- Pyruvate kinase deficiency
Globin synthesis defect
- sickle cell disease
- Alpha-thalassemia, e.g. HbH disease
Extrinsic causes of hemolysis
Systemic conditions
- Sepsis
- Arteriovenous malformation
Alloimmunity (The neonatal or cord blood gives a positive direct Coombs test and the maternal blood gives a positive indirect Coombs test)
- Hemolytic disease of the newborn (ABO)
- Rh disease
- Hemolytic disease of the newborn (anti-Kell)
- Hemolytic disease of the newborn (anti-Rhc)
- Other blood type mismatches causing hemolytic disease of the newborn
Non-hemolytic causes
- Breastfeeding jaundice
- Breast milk jaundice
- Cephalohematoma
- Polycythemia
- Urinary tract infection
- Sepsis
- Hypothyroidism
- Gilbert’s syndrome
- Crigler-Najjar syndrome
- High GI obstruction (Pyloric stenosis, Bowel obstruction)
Conjugated (Direct) Liver causes
Infections
- Sepsis
- Hepatitis A
- Hepatitis B
- TORCH infections
Metabolic
- Galactosemia
- Alpha-1-antitrypsin deficiency, which is commonly missed, and must be considered in DDx
- Cystic fibrosis
- Dubin-Johnson Syndrome
- Rotor syndrome
- Drugs
- Total parenteral nutrition
- Idiopathic
Post-liver
Biliary atresia or bile duct obstruction
- Alagille syndrome
- Choledochal cyst
Drugs that may cause liver damage
Analgesics
- Paracetamol
- Aspirin
- Non-steroidal anti-inflammatory drugs
Cardiac drugs
- Methyldopa
- Amiodarone
Psychotropic drugs
- Monoamine oxidase inhibitors
- Phenothiazines (such as chlorpromazine)
Others
- Sodium valproate
- Oestrogens (oral contraceptives and hormone replacement therapy)
Diagnosis of Jaundice
The History
- Duration of jaundice
- Previous attacks of jaundice
- Pain
- Chills, fever, systemic symptoms
- Itching
- Exposure to drugs (prescribed and illegal)
- Biliary surgery
- Anorexia, weight loss
- Colour of urine and stool
- Contact with other jaundiced patients
- History of injections or blood transfusions
- Occupation
Differential diagnosis of neonatal cholestatic liver disorders
Structural
- Extrahepatic biliary atresia
- Choledochal cyst
- Caroli’s syndrome
- Choledocholithiasis
- Alagille’s syndrome
- Nonsyndromic bile duct paucity
- Undersized extrahepatic biliary system (biliary hypoplasia)
- Neonatal sclerosing cholangitis
InfectionViral
- Bacterial infection (sepsis or remote from liver [eg, urinary tract infection])
- Toxoplasmosis
- Syphilis
- Metabolic
- Alpha-1-antitrypsin deficiency
- Galactosemia
- Tyrosinemia
- Hereditary fructose intolerance
- Glycogen storage disease type IV
Lipid storage disease
- – Niemann-Pick disease type A
- – Niemann-Pick disease type C
- – Gaucher’s disease
- – Wolman’s disease
- Mitochondrial enzymopathies (including fatty acid oxidation disorders)
- Peroxisomal disorders (eg, Zellweger syndrome)
- Bile acid synthesis disorders
Progressive familial intrahepatic cholestasis syndromes
- – FIC-1 protein deficiency (PFIC 1)
- – Bile salt export pump deficiency (PFIC 2)
- – MDR3 protein deficiency (PFIC 3)
- Urea cycle defects
- Genetic
- Cystic fibrosis
- Trisomy 21Trisomy 18
- Neoplastic
- Neuroblastoma
- Hepatoblastoma
- Histiocytosis toxic
Drug-induced
- Total parenteral nutrition
- Endocrine
- Panhypopituitarism
- Hypothyroidism
- Neonatal lupus erythematosus
- VascularBudd-Chiari syndrome
- Congestive heart failure
- Hepatic hemagiomatosisIdiopathic
- Initial investigations for conjugated hyperbilirubinemia
Blood
- Liver panel: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, conjugated bilirubin and albumin
- Coagulation studies (prothrombin time/international normalized ratio, partial thromboplastin time)
- Complete blood count and differential with a smear
- Toxoplasmosis, other infections, rubella, Cytomegalovirus infection and herpes simplex (TORCH) serology
- Blood culture
- Hepatitis B surface antigenGlucose/serum lactate/serum amino acids/ammonia
- Thyroxine, thyroid-stimulating hormone
- Iron studies, ferritin
- Galactosemia screen
Urine
- Reducing substances
- Organic acids
- Bacterial culture
- Urine Cytomegalovirus (positive result before four weeks of age is highly suggestive of congenital Cytomegalovirus
- Conjugated bilirubin present, urobilinogen > 2 units but variable (except in children). Kernicterus is a condition not associated with increased conjugated bilirubin.
- Plasma protein show characteristic changes.
- Plasma albumin level is low but plasma globulins are raised due to an increased formation of antibodies.
Imaging Test
- Ultrasonography – is the first line imaging investigation in patients with jaundice, right upper quadrant pain, or hepatomegaly. It is non-invasive, inexpensive, and quick but requires experience in technique and interpretation. Ultrasonography is the best method for identifying gallbladder stones and for confirming extrahepatic biliary obstruction as dilated bile ducts are visible. It is good at identifying liver abnormalities such as cysts and tumors and pancreatic masses and fluid collections, but visualization of the lower common bile duct and pancreas is often hindered by overlying bowel gas. Computed tomography is complementary to ultrasonography and provides information on liver texture, gallbladder disease, bile duct dilatation, and pancreatic disease. Computed tomography is particularly valuable for detecting small lesions in the liver and pancreas.
- Cholangiography – identifies the level of biliary obstruction and often the cause. Intravenous cholangiography is rarely used now as opacification of the bile ducts is poor, particularly in jaundiced patients, and anaphylaxis remains a problem. Endoscopic retrograde cholangiopancreatography is advisable when the lower end of the duct is obstructed (by gallstones or carcinoma of the pancreas). The cause of the obstruction (for example, stones or parasites) can sometimes be removed by endoscopic retrograde cholangiopancreatography to allow cytological or histological diagnosis.
- Percutaneous transhepatic cholangiography – is preferred for hilar obstructions (biliary stricture, cholangiocarcinoma of the hepatic duct bifurcation) because better opacification of the ducts near the obstruction provides more information for planning subsequent management. Obstruction can be relieved by insertion of a plastic or metal tube (a stent) at either endoscopic retrograde cholangiopancreatography or percutaneous transhepatic cholangiography.
- Magnetic resonance cholangiopancreatography – allows non-invasive visualization of the bile and pancreatic ducts. It is superseding most diagnostic endoscopic cholangiopancreatography as faster magnetic resonance imaging scanners become more widely available.
- Liver biopsy – Percutaneous liver biopsy is a day case procedure performed under local anesthetic. Patients must have a normal clotting time and platelet count and ultrasonography to ensure that the bile ducts are not dilated. Complications include bile leaks and hemorrhage, and overall mortality is around 0.1%. A transjugular liver biopsy can be performed by passing a special needle, under radiological guidance, through the internal jugular vein, the right atrium, and inferior vena cava and into the liver through the hepatic veins.
- Measurement of Bilirubin Levels – Bilirubin level can be checked through the biochemical method, Bilimeter or transcutaneous bilirubinometer (rx–rx).
- Biochemical – The gold standard method for bilirubin estimation is the total and conjugated bilirubin assessment based on the van den Bergh reaction ([rx, rx].
- Millimeter – Spectrophotometry is the base of Bilimeter and it assesses total bilirubin in the serum. Because of the predominant unconjugated form of bilirubin, this method has been found a useful method in neonates.
- Transcutaneous Bilirubinometer – This method is noninvasive and is based on the principle of multi-wavelength spectral reflectance from the bilirubin staining in the skin [rx]. The accuracy of the instrument may be affected by the variation of skin pigmentation and its thickness [rx].
- Clinical Approach to Jaundice – The initial step in the evaluation of any newborn for jaundice is to differentiate between physiological and pathological jaundice. A helpful algorithm as adapted by AAP (2004b) [rx] is as follows.
- Dependency on Newborn Period or Preterm – Preterm intervention values are different and depend on the degree of prematurity and birth weight [rx–rx].
- Evidence of Hemolysis – Onset of jaundice within 24 h, presence of pallor and hydrops, presence of hepatosplenomegaly, presence of hemolysis on the smear of peripheral blood, increased count of reticulocyte (>8%), rapid rise of bilirubin (>5 mg/dl in 24 h or >0.5 mg/dl/hr) or a family history of considerable jaundice should create a suspicion of hemolytic jaundice [rx].
- Instructions and Precautionary Measure for Parents during Physiological Jaundice – The benign nature of jaundice should be explained and demonstrated to the parents. The mother should be encouraged to breast-feed her baby frequently and exclusively, at least eight to twelve times per day for initial several days, with no top feeds or glucose water whatsoever [rx–rx]. The mother should be told to bring the baby to the hospital if the color on the legs looks as yellow as the face.
- Abdominal sonography – is a valuable screening test in the jaundiced patient [rx]. The demonstration of biliary ductal dilation, gallstones, hepatic mass lesion, or an enlarged or abnormally shaped pancreas directs further investigation or therapy. Sonography is noninvasive, readily available in most hospitals, does not involve radiation exposure, and is cheaper than CT or other procedures in which the bile ducts are directly opacified. It may also allow guided biopsy or drainage of lesions in the liver or pancreas. However, sonography may be technically unsatisfactory in up to 40% of cases, primarily due to obesity or to the accumulation of bowel gas, which prevents transmission of sound waves.
- Hepatobiliary scintigraphy – had little to contribute to the differential diagnosis of jaundice except in the instance of neonatal hepatitis versus biliary atresia or the occasional need for objective assessment of liver size. However, the development of new radionuclide agents with improved hepatic extraction and biliary excretion, improved imaging techniques, and the application of computer assistance to the interpretation of dynamic scans have transformed HBS into an accurate modality for the diagnosis of large bile duct obstruction and may also prove useful in demonstrating intrahepatic cholestasis[rx].
- Percutaneous transhepatic cholangiography – involves passage of a thin needle into the liver under fluoroscopic guidance and injection of contrast into the biliary tree [rx]. The procedure is easily available, its cost is generally less than that of ERCP, and a local anesthetic injection over the right flank is the only sedative or anesthetic medication required. Dilated ducts are opacified in 95 to 100% of cases, but even nondilated ducts are opacified in 60 to 95% of cases. A dilated, the obstructed duct may be decompressed percutaneously by the passage of a guide wire and cannula through the right flank incision.
- Endoscopic retrograde cholangiopancreatography – is performed by passing a flexible fiberoptic endoscope into the patient’s duodenum, inserting a cannula into the pancreatic and common bile ducts and injecting radiopaque contrast into these structures under fluoroscopy [rx]. ERCP has the advantage of visualization and potential biopsy of the stomach and duodenum (since the scope is side-viewing. the esophagus cannot be seen). The procedure diagnoses pancreatic carcinoma in at least 90% of cases and can furnish visual (photographic and radiographic) and histologic proof of ampullary tumors.
Treatment of Jaundice
Key elements from the American Academy of Pediatrics guideline on the management of hyperbilirubinemia in the newborn at ≥ 35 weeks’ gestation[rx]
- Promote and support successful breastfeeding
- Establish nursery protocols for the identification and evaluation of hyperbilirubinemia
- Measure the total serum or transcutaneous bilirubin level in infants with jaundice in the first 24 hours
- Recognize that visual estimation of the degree of jaundice can lead to errors, particularly in darkly pigmented infants
- Interpret all bilirubin levels according to the infant’s age in hours
- Recognize that infants at less than 38 weeks’ gestation, particularly those who are breastfed, are at higher risk of hyperbilirubinemia and require closer surveillance and monitoring
- Perform a systematic assessment on all infants before discharge for the risk of severe hyperbilirubinemia
- Provide parents with written and verbal information about jaundice in the newborn
- Provide appropriate follow-up based on the time of discharge and the risk assessment
- Treat jaundice in the newborn, when indicated, with phototherapy or exchange transfusion
The treatment options for jaundice include phototherapy further subdivided to conventional, intensive and exchange transfusion, and pharmacological treatment subdivided to phenobarbitone, intravenous immunoglobulins (IVIG), metalloporphyrins and follow up remedies [rx].
Phototherapy
Hyperbilirubinemia can be treated easily without or with a minimal adverse effect with phototherapy [rx, rx]. The efficacy of phototherapy depends on surface area exposed to phototherapy: Double surface phototherapy may be more effective than single surface phototherapy [rx]. The spectrum of light source: Special blue tubes with the mark F20T12/BB should be used rather than F20T12/B lights and Irradiance or energy output may be increased in a phototherapy unit by lowering the distance of the neonate to within 15–20 cm [rx, rx]. Continuous phototherapy is better than intermittent phototherapy. Phototherapy should not be interrupted except during breastfeeding or nappy change [rx, rx–rx].
Conventional Phototherapy
- One can use conventional or fiber-optic phototherapy units provided jaundice is non-hemolytic or its progression is slow.
Intensive Phototherapy
- In the circumstances including hemolytic jaundice, rapidly increasing bilirubin, or ineffectiveness of a conventional unit, using intensive phototherapy is warranted. Placing the baby on the bili-blanket and using additional overhead phototherapy units contain blue lights and then lowering the phototherapy units to within a distance of 15–20 cm are two significant remedies [rx].
Exchange Transfusion
Through exchange transfusion, bilirubin and hemolytic antibodies are removed [rx].
- Rh Isoimmunization – Always, Blood using for exchange transfusion should be negative Rh isoimmunization, negative for Rh factor. O (Rh) negative packed cells suspended in AB plasma will be the best choice. O (Rh) negative whole blood or cross-matched baby’s blood group (Rh negative) may also be used in an emergency [rx, rx].
- ABO Incompatibility – Only O-blood group should be used for exchange transfusion in newborns with ABO incompatibility. The best choice would be O group (Rh compatible) packed cells which are suspended in O group/AB plasma whole blood (Rh compatible with baby).
- Other situations – In the case of the Cross-matched with baby’s blood group blood volume used or double volume exchange should be kept in mind.
- Blood Volume Used – Partial exchange is done at birth in Rh hemolytic disease: 50-ml/kg of packed cells
- Double Volume Exchange – 2 × (80–100 ml/kg) × birth weight (kg)
Pharmacological Treatment
Pharmacological treatment of neonatal jaundice can further be categorized into different subheadings such as phenobarbitone, Intravenous immunoglobulins, and Metalloporphyrins etc. [rx, rx–rx].
- Bilirubin processing including hepatic uptake, conjugation, and its excretion are ameliorated by this agent thus helps in decreasing level of bilirubin. However,r the effect of phenobarbitone is not rapid and takes time to show. When used for 3–5 days in a dose of 5 mg/kg after birth prophylactically, it has shown to be effective in babies with hemolytic disease, extravasated blood and in pre-term without any significant side effects. There is a huge literature documenting the efficacy and mechanism of action and complications of treatment for Phenobarbital [rx–rx].
Intravenous Immunoglobulin (IVIG)
- High dose IVIG (0.5–1 gr/kg) has shown to be effective in decreasing the needs of exchange transfusion and phototherapy in babies with Rh hemolytic disease [rx–rx].
Metalloporphyrins
- These compounds are still experimental but showing promising results in various hemolytic and non-hemolytic settings without significant side effects [rx, rx–rx].
Fiber-optic blanket
- Another form of phototherapy is a fiberoptic blanket placed under the baby. This may be used alone or in combination with regular phototherapy.
Exchange transfusion to replace the baby’s damaged blood with fresh blood
- Exchange transfusion helps increase the red blood cell count and lower the levels of bilirubin. An exchange transfusion is done by alternating giving and withdrawing blood in small amounts through a vein or artery. Exchange transfusions may need to be repeated if the bilirubin levels remain high.
Adequate hydration with breastfeeding or pumped breast milk.
- The American Academy of Pediatrics recommends that, if possible, breastfeeding be continued. Breastfed babies receiving phototherapy who are dehydrated or have excessive weight loss can have supplementation with expressed breast milk or formula.
Follow-up
- Babies having roughly 20 mg/dl serum bilirubin and that requiring exchange transfusion should be kept under follow-up in the high-risk clinic for neurodevelopmental outcome [rx, rx]. Hearing assessment (Brainstem Evoked Response Audiometry (BAER)) should be done at 3 months of corrected age [rx].
Drugs Used in Hepatic Jaundice:
- Ursodeoxycholic acid (ursodiol): Helps dissolve gallstones.
- N-acetylcysteine: Antidote for acetaminophen overdose.
- Rifampicin: Antibiotic used in certain liver infections.
- Corticosteroids: For autoimmune liver diseases.
- Interferon: Antiviral medication for hepatitis.
- Ribavirin: Antiviral medication for hepatitis.
- Lamivudine: Antiviral medication for hepatitis B.
- Entecavir: Antiviral medication for hepatitis B.
- Tenofovir: Antiviral medication for hepatitis B and C.
- Sofosbuvir: Antiviral medication for hepatitis C.
Drug treatments
Doses are typical adult ranges and must be individualized by your clinician, especially with impaired liver function.
1) Ursodeoxycholic acid (UDCA)
Class: Bile acid (hydrophilic).
Dose/Time: 10–15 mg/kg/day in 2–3 divided doses, long-term if indicated.
Purpose: Improve cholestasis in diseases like primary biliary cholangitis and some intrahepatic cholestasis states.
Mechanism: Replaces toxic bile acids, stabilizes hepatocyte membranes, improves bile flow.
Side effects: Mild GI upset, weight gain, rare hair thinning.
2) Cholestyramine (for cholestatic pruritus)
Class: Bile acid sequestrant.
Dose/Time: 4 g 1–4 times daily; take ≥4–6 h apart from other meds.
Purpose: Reduce itching from bile acids.
Mechanism: Binds bile acids in gut, lowers enterohepatic circulation.
Side effects: Constipation, bloating, poor absorption of fat-soluble vitamins.
3) Rifampin (second-line anti-pruritic; specialist use)
Class: Enzyme inducer antibiotic.
Dose/Time: 150–300 mg twice daily if benefits outweigh risks.
Purpose: Refractory cholestatic itch.
Mechanism: Induces microsomal enzymes and pregnane X receptor pathways that modify pruritogens.
Side effects: Hepatotoxicity, drug interactions, orange body fluids.
4) Naltrexone (anti-pruritic; off-label)
Class: Opioid receptor antagonist.
Dose/Time: Start 12.5–25 mg daily, increase to 50 mg daily as tolerated.
Purpose: Break itch-scratch cycle mediated by endogenous opioids.
Mechanism: Blocks μ-opioid receptors; shifts itch signaling.
Side effects: Nausea, insomnia, withdrawal-like symptoms if on opioids.
5) Sertraline (itch adjunct in some patients)
Class: SSRI antidepressant.
Dose/Time: 50–100 mg daily.
Purpose: Reduce itch perception, improve mood/sleep; sometimes helps in cholestatic itch.
Mechanism: Central modulation of serotonin pathways.
Side effects: GI upset, sexual dysfunction, hyponatremia in elderly.
6) Vitamin K (phytonadione) for coagulopathy
Class: Fat-soluble vitamin.
Dose/Time: 5–10 mg PO/IV daily for 1–3 days if deficiency suspected (e.g., prolonged INR from cholestasis/malabsorption).
Purpose: Correct vitamin K deficiency–related bleeding risk.
Mechanism: Restores γ-carboxylation of clotting factors II, VII, IX, X.
Side effects: Rare anaphylactoid reaction with IV (use slow infusion).
7) Prednisolone/Prednisone ± Azathioprine (autoimmune hepatitis)
Class: Corticosteroid ± antimetabolite.
Dose/Time: Prednisolone 30–40 mg/day taper; add azathioprine 1–2 mg/kg/day for steroid-sparing; months to years under specialist care.
Purpose: Suppress immune attack on hepatocytes and resolve jaundice.
Mechanism: Broad anti-inflammatory and T-cell suppression.
Side effects: Infection risk, weight gain, diabetes, bone loss; azathioprine can cause cytopenias and cholestasis.
8) N-Acetylcysteine (NAC) in acetaminophen toxicity and sometimes acute liver failure
Class: Antidote/antioxidant.
Dose/Time: IV or PO protocols per hospital (e.g., IV 150 mg/kg load then infusions).
Purpose: Stop ongoing injury and improve survival in acute toxic injury.
Mechanism: Replenishes glutathione; detoxifies NAPQI; antioxidant effects.
Side effects: Nausea, rare anaphylactoid reaction (treatable).
9) Direct-acting antivirals for hepatitis C (e.g., sofosbuvir/velpatasvir)
Class: Antiviral combination.
Dose/Time: Fixed-dose tablet once daily for 12 weeks (typical).
Purpose: Cure HCV, reduce inflammation, resolve jaundice over time.
Mechanism: Inhibits viral polymerase/NS5A replication complex.
Side effects: Headache, fatigue; major drug-drug interaction checks required.
10) Antivirals for hepatitis B (e.g., tenofovir disoproxil fumarate or entecavir)
Class: Nucleos(t)ide analogs.
Dose/Time: Tenofovir DF 300 mg daily or entecavir 0.5–1 mg daily, long-term.
Purpose: Suppress HBV, limit inflammation/fibrosis, prevent flares.
Mechanism: Inhibits HBV polymerase.
Side effects: Tenofovir: renal/bone monitoring; Entecavir: generally well tolerated.
Other common supportive meds your clinician may use (not counted in the 10 above): lactulose/rifaximin for encephalopathy, diuretics for ascites, fat-soluble vitamin A/D/E/K replacement, antibiotics for infections, and PPIs/H2 blockers if steroid therapy or variceal risks are present.
Dietary molecular supplements
Supplements can interact with medications and some are harmful in liver disease. Discuss every supplement with your clinician. Avoid multi-herb “detox” products with unknown ingredients.
1) Coffee (brew, not energy drinks)
Dose: 2–4 cups/day if tolerated.
Function: Associated with lower liver fibrosis and HCC risk in studies.
Mechanism: Antioxidants, diterpenes, and adenosine modulation reduce inflammation and fibrosis.
2) Omega-3 fatty acids (EPA/DHA)
Dose: 1–2 g/day combined EPA+DHA.
Function: Improves triglycerides and may help fatty liver.
Mechanism: Anti-inflammatory lipid mediators; lowers hepatic fat synthesis.
3) Vitamin E (for non-diabetic NASH, specialist-guided)
Dose: 800 IU/day (alpha-tocopherol) if appropriate.
Function: Antioxidant that may improve steatohepatitis.
Mechanism: Scavenges reactive oxygen species in hepatocytes.
Caution: Possible bleeding risk/long-term safety debates; avoid if cirrhosis/diabetes unless advised.
4) Zinc
Dose: 25–50 mg elemental zinc/day for limited periods; add copper monitoring if long-term.
Function: Supports ammonia handling and immune function.
Mechanism: Cofactor for urea cycle enzymes and antioxidant defense.
5) Selenium
Dose: 100–200 mcg/day.
Function: Antioxidant support.
Mechanism: Integral to glutathione peroxidases, reduces oxidative stress.
6) S-adenosyl-L-methionine (SAMe)
Dose: 800–1600 mg/day in divided doses.
Function: May improve cholestasis and mood symptoms in some patients.
Mechanism: Donates methyl groups; supports glutathione synthesis.
7) TUDCA (tauroursodeoxycholic acid) supplement
Dose: Common over-the-counter doses range 250–500 mg/day; medical-grade dosing varies—ask your doctor.
Function: Bile flow support and cellular stress reduction.
Mechanism: Hydrophilic bile acid that reduces ER stress and stabilizes membranes.
8) Curcumin (turmeric extract standardized)
Dose: 500–1000 mg/day with piperine-free or carefully monitored formulas (piperine can raise drug levels).
Function: Anti-inflammatory and antioxidant effects.
Mechanism: NF-κB pathway modulation; free radical scavenging.
Caution: Rare hepatotoxicity reported—stop if enzymes rise.
9) Betaine (trimethylglycine)
Dose: 2–6 g/day divided.
Function: Methyl donor; may help fatty liver in some small studies.
Mechanism: Supports homocysteine methylation and hepatic fat export.
10) Phosphatidylcholine (PC)
Dose: 1.2–2.7 g/day.
Function: Cell-membrane support and bile composition aid.
Mechanism: Supplies membrane phospholipids; may improve VLDL export.
Regenerative / stem-cell-related” therapies
These are not self-treatments. Several remain investigational and are used only in trials or specialist centers. I’ll note typical research dosing when established; otherwise, dosing varies and is determined by protocols.
1) Pegylated Interferon-α (for HBV/HDV in selected patients)
Dose: PegIFN-α2a 180 mcg once weekly (duration and eligibility vary).
Function/Mechanism: Immune modulation to clear or suppress hepatitis viruses; can improve hepatic inflammation and jaundice over time.
Cautions: Flu-like symptoms, depression, cytopenias; not for decompensated cirrhosis.
2) Thymosin alpha-1 (used in some countries for chronic hepatitis)
Dose: 1.6 mg subcutaneously twice weekly (regimens vary).
Function/Mechanism: Enhances T-cell function and antiviral responses.
Cautions: Variable evidence; use only under specialist guidance.
3) Granulocyte colony-stimulating factor (G-CSF) in acute-on-chronic liver failure (ACLF) — investigational
Dose in trials: ~5 µg/kg/day SC for 5 days; protocols vary.
Function/Mechanism: Mobilizes bone-marrow stem cells; may aid liver regeneration in some studies.
Cautions: Mixed evidence; infection/leukocytosis risks.
4) Mesenchymal stem cell (MSC) infusions — clinical trials
Dose: Protocol-defined; no over-the-counter use.
Function/Mechanism: Paracrine anti-inflammatory and anti-fibrotic effects; potential hepatocyte support.
Cautions: Experimental; seek ethics-approved trials only.
5) Albumin dialysis systems (MARS, Prometheus) — bridge therapy
Dose: Per hospital protocol (sessions hours–days).
Function/Mechanism: Removes protein-bound toxins (bile acids, bilirubin) to stabilize patients with severe cholestasis or liver failure while underlying cause is treated.
Cautions: ICU-level care; not a cure.
6) Hepatocyte or auxiliary liver transplantation — highly specialized
Dose: Surgical/procedural; selection criteria strict.
Function/Mechanism: Replaces failing hepatocyte function; definitive for end-stage disease or acute liver failure not recovering.
Cautions: Lifelong immunosuppression, infection risk, rejection, cost.
Surgeries/procedures
Many cases of hepatic jaundice are not surgical. Procedures are used for diagnosis, complications, mixed pathology, or end-stage disease.
1) Liver biopsy (percutaneous or transjugular)
Procedure: Needle samples liver tissue; transjugular route used when clotting risk is high.
Why done: Confirm cause (autoimmune, NASH, drug-induced, cholestatic diseases) and stage fibrosis, which guides therapy.
2) ERCP with limited intrahepatic intervention (selected cholestatic disorders)
Procedure: Endoscopic scope into bile duct to treat strictures or stones; stents can be placed.
Why done: If imaging shows intrahepatic duct strictures or stone migration causing a mixed cholestatic picture.
3) Percutaneous transhepatic biliary drainage (PTBD)
Procedure: Radiologist places a catheter through the liver into bile ducts to drain bile.
Why done: Severe cholestasis with segmental obstruction not accessible by ERCP in secondary sclerosing cholangitis or complex strictures.
4) Transjugular intrahepatic portosystemic shunt (TIPS)
Procedure: Creates a channel between portal and hepatic veins.
Why done: Not for jaundice directly, but for complications (refractory ascites/variceal bleeding) that worsen overall liver function and can indirectly affect bilirubin handling.
5) Liver transplantation
Procedure: Replace diseased liver with a donor liver.
Why done: End-stage liver disease or acute liver failure with poor recovery chances—definitive solution for persistent hepatic jaundice when the liver cannot recover.
Preventions
Get vaccinated against hepatitis A and B if not immune.
Do not drink alcohol if you have any liver disease; never binge drink.
Use medicines carefully: follow doses; avoid double-dosing combination cold/pain pills that contain acetaminophen.
Avoid risky injections or needle sharing; use sterile equipment for tattoos/piercings.
Practice safer sex; use condoms to reduce viral hepatitis spread.
Keep a healthy weight; aim for a waistline and BMI in a healthy range.
Control diabetes, blood pressure, and lipids with food, activity, and prescribed meds.
Avoid raw/undercooked shellfish and unsafe water, especially when traveling.
Check herbs and supplements with your clinician; avoid unknown “liver cleanses.”
Routine checkups if you take long-term potentially hepatotoxic drugs (e.g., TB therapy, methotrexate); do scheduled labs.
When to see a doctor urgently
Rapidly deepening yellow color of skin/eyes over days.
Very dark urine and clay-colored stools lasting more than 24–48 hours.
Severe itching preventing sleep.
Confusion, drowsiness, personality change, or tremor (possible hepatic encephalopathy).
Easy bruising or bleeding, nosebleeds, or black stools.
Severe right-upper abdominal pain, fever, or vomiting.
New swelling of the belly or legs, or sudden weight gain from fluid.
Inability to keep food/fluids down, fainting, or signs of dehydration.
If pregnant and jaundiced—seek care immediately.
Any jaundice in a newborn or child should be assessed promptly.
What to eat and what to avoid
What to eat
Lean proteins: fish, skinless poultry, beans, tofu, low-fat dairy—support healing.
High-fiber carbs: oats, brown rice, barley, whole-grain bread—support gut microbiome and bile acid metabolism.
Colorful vegetables and fruits: antioxidants that fight liver inflammation (e.g., leafy greens, berries, citrus).
Healthy fats: olive oil, avocado, nuts, and seeds—improve lipid profile and satiety.
Plenty of water—supports circulation and kidney function; limit sugary drinks.
What to avoid
- Alcohol—even “social” amounts can harm a diseased liver.
- Very high-sugar and refined carb foods—sodas, pastries, candy; these drive fat accumulation in the liver.
- Large amounts of deep-fried foods and trans fats—increase oxidative stress.
- Raw/undercooked shellfish—infection risk.
- Unregulated herbal mixtures or bodybuilding supplements—common source of drug-induced liver injury.
Risk factors
Underlying conditions that may cause jaundice to include
- Acute inflammation of the liver – This may impair the ability of the liver to conjugate and secrete bilirubin, resulting in a buildup.
- Inflammation of the bile duct – This can prevent the secretion of bile and removal of bilirubin, causing jaundice.
- Obstruction of the bile duct – This prevents the liver from disposing of bilirubin.
- Hemolytic anemia – The production of bilirubin increases when large quantities of red blood cells are broken down.
- Gilbert’s syndrome – This is an inherited condition that impairs the ability of enzymes to process the excretion of bile.
- Cholestasis –This interrupts the flow of bile from the liver. The bile containing conjugated bilirubin remains in the liver instead of being excreted.
- Crigler-Najjar syndrome – This is an inherited condition that impairs the specific enzyme responsible for processing bilirubin.
- Dubin-Johnson syndrome – This is an inherited form of chronic jaundice that prevents conjugated bilirubin from being secreted from the cells of the liver.
- Pseudojaundice – This is a harmless form of jaundice. The yellowing of the skin results from an excess of beta-carotene, not from an excess of bilirubin. Pseudojaundice usually arises from eating large quantities of carrot, pumpkin, or melon.
REferences
